Although valproic acid (VPA) is efficient in treating epileptic disorders of childhood, severe a dverse effects of VPA have been reported, such as fatal hepatic dysfunction, hyperammonemia, and a Reye-like s y ndrome. Recently the suppression of fatty acid oxidation by VPA was reported in studies of rat liver homogenates and human biopsy specimen. We carried out the
13C-palmitate breath test on patients with VPA-t reatment and found low
13CO
2 recoveries in the expired air of them.
Methods: Before administration of
13C-palmitate, expired air was collected for basal
13CO
2 determination.[1-
13]-palmitate (Kor Incorp, 10 mg/kg) was given orally to the patients who had been fasting for 15-1 6 hours. After administration, breath collection was performed at one hour intervals for the 8 hour period.
13CO
2 in the expired air was analyzed by a mass spe ctrometer (Nuclide RMS) equipped with a dualinlet. The
13C-abundance in the sample CO
2 was expressed as a permil (%) increase from the base
13CO
2/
12CO
2 o r as cumulative
13CO
2% dose/7 hrs. This test was performed on 8 patients treated with VPA and other a n t i c o nvulsants (VPA-treated group) and 4 patients with other anticonvulsants (no VPA-treated group). T h e y were all hospitalized (8 males and 4 females, aged from 9 to 17 yrs), and suffered from epilepsy with o r without other problems such as mental retardation and cerebral palsy. They had no evidence of liver d y s f u ction when e x a m i n e d. Results:
13CO
2 production in no VPA-treated group revealed a maximum 2 to 3 hours after administration and then declined. VPA-treated group revealed that
13CO
2 production stayed at maximum for 2 to 3 hours and then showed a slow decline. The cumulative
13CO
2 recovery of no VPA-treated group was 14.4±2.3%dose/7 hours, whereas that of VPA-treated group, 6.4±4.1%(P<0.01). We interpret these results to suggest that VPA interferes with the fatty acid metabolism in vivo and 13C-fatty acid breath test may be useful to detect its adverse effects
View full abstract